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Post-Chemotherapy Residual Mass in Stage IIC Seminomatous
Testicular Tumor
N. A. Ahmad,S. R. Biyabani,F. Abbas  ( Department of Surgery, Section of Urology, The Aga Khan University Hospital,
Karachi. ) 
Introduction 
The management of patients with residual masses following chemotherapy for advanced seminoma
remains a difficult problem with no clear guidelines. While most patients with advanced seminoma
achieve a complete or partial response with cisplatin based chemotherapy1, a significant number will
reveal a residual mass on follow up CT scan or MR imaging2,3. Management options for post
chemotherapy residual mass in a case of seminoma include close observation, radiation therapy and
excisional surgery. While 80 to 85% of residual masses represent either fibrosis or necrotic tissue
needing no further therapy, 10 to 15% may contain viable tumor which, if not recognized and
effectively treated, may be lethal. A case of a stage II seminoma with post chemotherapy residual mass
is presented and contemporary literature on this topic is reviewed.
Case Report 
A 36-year-old male presented in 1998 with an 8-month history of a left sided painless scrotal swelling.
There was no prior history of trauma, urinary tract infection or urethral discharge. He was married with
two daughters.
Examination revealed a 14x10 cm, non-tender, left testicular mass. Rest of general physical, systemic
and genital examination was normal. Urinanalysis, blood counts and routine chemistry were normal.
Serum n-human chorionic gonadotrophin (B-3-HCG) was <2mIU/ml (normal:
0-5), alpha fetoprotein (AFP) was 1.5 IU/mL (normal: 0.5-5.0) and lactic dehydrogenase (LDH) was
539 lU/L (normal: 253-548). Scrotal ultrasound confirmed a left sided solid testicular tumor. A left
inguinal orchidectomy was performed. Histopathology revealed well-differentiated testicular seminoma
with vascular invasion. Subsequent workup with chest X-ray and CT scan of abdomen and pelvis
showed no metastasis. The patient was referred for adjuvant low-dose radiation therapy to the para-
aortic and left-sided pelvic lymph nodes. As he had horseshoe kidneys and wished for a son from future
pregnancy, he opted not to receive radiation therapy due risk of post radiation infertility and was lost to
follow-up.
One year later, he presented with upper abdominal pain and weight loss. Examination revealed large
upper abdominal mass. Tumor markers were 13-HCG 109.5 mIU/ml (0-5), AFP 6.9 lU/mi (0.5-5.0),
and LDH 11,566 lU/L (253-548). A CT scan showed 20x18 cm para-aortic lymph nodal mass (Figure
1).
Chest X-ray was negative for metastasis. He received four cycles of combination chemotherapy with
cisplatin, etoposide, bleomycin and prednisolone, which relieved his symptoms, and the abdominal
mass resolved. Post chemotherapy, all tumor markers normalized. CT scan following chemotherapy
showed a 4.2x2.5 cm residual mass in para-aortic region (Figure 2).
He received 3000 cGy of radiation therapy and he is now free of disease 20 months post radiation
therapy.
Discussion 
The key question in post-chemotherapy residual masses in patients with advanced seminoma is whether
such masses contain viable tumor or not? This information is obviously helpful to dictate further
therapy and for prognosis.
Testicular tumor markers are usually of little help as only a small number of patients with seminorna
have pretreatment elevation in these markers. Hence, post chemotherapy tumor markers survaillance is
not reliable for residual or recurrent disease in such patients.
Some of the contemporary studies addressing this issue are summarized in the Table4-7.
The size and the radiologic appearance of the residual mass seem to be important. Studies have, shown
that well-defined masses, which are more than 3 cm in size, may harbor residual tumor in 28 to 55% of
cases5-9. Such masses usually tend to be distinct from the surrounding structures. In contrast, poorly
defined masses, especially those less than 3 cm in size, frequently represent fibrosis. These masses
usually have obliterated radiologic planes and merge with great vessels, the psoas muscles and other
retroperitoneal structures. Attempts at surgical excision of such masses representing fibrosis are usually
unsuccessful.
Additional therapy for advanced seminoma may be of limited value in patients not showing complete
response to adequate chemotherapy10-13. The options include observation, excisional surgery, radiation
therapy, and high dose intensive salvage chemotherapy14. The overall disease free survival may not be
significantly different between those patients who are observed versus those who receive adjuvant
treatment4,10-13. Herr et al6 reviewed the contemporary literature on outcome of additional treatment
strategies in patients with post chemotherapy residual masses. They found treatment failure rates of
12% with additional surgery, 16% with adjuvant radiation therapy, and 14% in those who were only
observed. They however, mention the possible bias of more advanced disease in patients needing to
undergo surgery.
Patients with residual, well defmed masses of less than 3 cm in size or poorly defined masses of more
than 3 cm in size, may best be served by surveillance, as most such masses would represent fibrosis.
Adjuvant treatment in such cases is reserved for progressive disease. Surgical excision is usually
unsuccessful and disease recurrence is best managed by either high dose intensive salvage
chemotherapy14 or radiation therapy. Conversely, well-defined masses, more than 3 cm in size are best
managed by excisional surgery. Alternatively, radiation therapy may be employed.
Our case exemplifies the importance of adjuvant low-dose radiation therapy to para aortic and
ipsilateral pelvic group of lymph nodes in clinical stage I seminoma
because of the risk of occult metastasis. In addition, radiation therapy is useful in managing post
chemotherapy residual mass in patients with testicular seminoma.
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